Elevation Oncology initiated dosing of EO-3021, a Claudin 18.2 ADC, in combination with ramucirumab or dostarlimab for advanced gastric/GEJ cancer patients.
William Blair analyst Andy Hsieh praises Elevation Oncology for its promising cancer therapies, particularly its antibody-drug conjugate expertise targeting Claudin 18.2 and HER3, highlighting a favorable risk-to-reward ratio and significant market potential.
Recent preclinical studies have shown that EO-3021, an antibody-drug conjugate targeting CLDN18.2, exhibits efficacy in models of gastric adenocarcinoma when combined with VEGFR-2 or PD-1 inhibitors.
Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.